207 related articles for article (PubMed ID: 35418124)
1. Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer.
Hao Y; He B; Wu L; Li Y; Wang C; Wang T; Sun L; Zhang Y; Zhan Y; Zhao Y; Markowitz S; Veigl M; Conlon RA; Wang Z
Nat Commun; 2022 Apr; 13(1):1974. PubMed ID: 35418124
[TBL] [Abstract][Full Text] [Related]
2. The 'New (Nu)-clear' evidence for the tumor-driving role of PI3K.
Pozo FM; Hunter T; Zhang Y
Acta Mater Med; 2022; 1(2):193-196. PubMed ID: 37200937
[TBL] [Abstract][Full Text] [Related]
3. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations of PIK3CA in human cancers.
Samuels Y; Velculescu VE
Cell Cycle; 2004 Oct; 3(10):1221-4. PubMed ID: 15467468
[TBL] [Abstract][Full Text] [Related]
6. Human tumor mutants in the p110alpha subunit of PI3K.
Liu Z; Roberts TM
Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
[TBL] [Abstract][Full Text] [Related]
7. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
8. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
[TBL] [Abstract][Full Text] [Related]
9. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Zhao L; Vogt PK
Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
[TBL] [Abstract][Full Text] [Related]
10. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
Wei Y; Lin S; Zhi W; Chu T; Liu B; Peng T; Xu M; Ding W; Cao C; Wu P
J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
[TBL] [Abstract][Full Text] [Related]
11. In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas.
Madhukar G; Subbarao N
J Biomol Struct Dyn; 2022 Jul; 40(10):4697-4712. PubMed ID: 33356909
[TBL] [Abstract][Full Text] [Related]
12. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
Zhao L; Vogt PK
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2652-7. PubMed ID: 18268322
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition.
Spangle JM; Von T; Pavlick DC; Khotimsky A; Zhao JJ; Roberts TM
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24427-24433. PubMed ID: 32929011
[No Abstract] [Full Text] [Related]
14. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with
Jhaveri K; Chang MT; Juric D; Saura C; Gambardella V; Melnyk A; Patel MR; Ribrag V; Ma CX; Aljumaily R; Bedard PL; Sachdev JC; Dunn L; Won H; Bond J; Jones S; Savage HM; Scaltriti M; Wilson TR; Wei MC; Hyman DM
Clin Cancer Res; 2021 Jan; 27(2):447-459. PubMed ID: 33148674
[TBL] [Abstract][Full Text] [Related]
15. A novel carcinogenic PI3Kα mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain.
Ghalamkari S; Alavi S; Mianesaz H; Khosravian F; Bahreini A; Salehi M
Life Sci; 2021 Mar; 269():118759. PubMed ID: 33189828
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus.
Jenkins ML; Ranga-Prasad H; Parson MAH; Harris NJ; Rathinaswamy MK; Burke JE
Nat Commun; 2023 Jan; 14(1):181. PubMed ID: 36635288
[TBL] [Abstract][Full Text] [Related]
17. Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.
Hao Y; Zhao S; Wang Z
Toxicol Pathol; 2014 Jan; 42(1):140-7. PubMed ID: 24178578
[TBL] [Abstract][Full Text] [Related]
18. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
Ghodsinia AA; Lego JMT; Garcia RL
Cells; 2020 Apr; 9(5):. PubMed ID: 32365913
[TBL] [Abstract][Full Text] [Related]
19. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
Tanaka H; Yoshida M; Tanimura H; Fujii T; Sakata K; Tachibana Y; Ohwada J; Ebiike H; Kuramoto S; Morita K; Yoshimura Y; Yamazaki T; Ishii N; Kondoh O; Aoki Y
Clin Cancer Res; 2011 May; 17(10):3272-81. PubMed ID: 21558396
[TBL] [Abstract][Full Text] [Related]
20. Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival.
Kumar A; Redondo-Muñoz J; Perez-García V; Cortes I; Chagoyen M; Carrera AC
Mol Cell Biol; 2011 May; 31(10):2122-33. PubMed ID: 21383062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]